علاج ورم الخلايا العملاقة للعظم غير القابل للاستئصال أو غير الصالح للجراحة أو النقيلي

References

DOI: 10.3390/curroncol31040157

• At present, this agent is indicated for unresectable GCTB or in case of significant functional impairment following resection.
• Denosumab monotherapy once every 3 months is currently the standard strategy for inoperable patients and those with metastatic GCTB.
• Denosumab is contraindicated for pregnant patients.
• Therefore, extending the dosing period (120 mg every 3 months) is recommended to reduce the incidence of complications.
• Therefore, ZA may be an alternative treatment option, particularly in developing countries.
• After treatment with denosumab, tumor enlargement ceases in 99% of cases.
• and all symptoms were relieved via bone formation and possible tumor shrinkage.